Skip to main content

Abrilada News

Data Suggests TNF Inhibitors Help Prevent Serious Complications in Children with Crohn's Disease

FRIDAY, Dec. 27, 2024 A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn’s disease. A new study published recently in the journal Gut shows c...

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar Abrilada

NEW YORK, October 5, 2023 – Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has designated Abrilada™ (adalimumab-afzb) as an interchangeable biosimilar to Hum...

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira

November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (a...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related condition support groups

Ankylosing Spondylitis, Crohn's Disease - Acute, Crohn's Disease - Maintenance, Crohn's Disease, Plaque Psoriasis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis

Abrilada patient information at Drugs.com